Patents Assigned to Cytograft Tissue Engineering, Inc.
-
Publication number: 20150088247Abstract: A single-layer tissue sheet having a puncture strength of 2 kgf to 6 kgf. A valve, such as a heart valve, made of one or more leaflets formed from a single-layer tissue sheet. A method of making a tissue sheet having a puncture strength of 2 kgf to 5 kgf. The ultra-strong tissue sheets described herein have very long culture times, such as in excess of 20 weeks. Valves that comprise one or more leaflets made from the ultra-strong tissue sheets described herein may be delivered via trans-cathete aortic valve implantation.Type: ApplicationFiled: March 25, 2013Publication date: March 26, 2015Applicant: Cytograft Tissue Engineering, Inc.Inventors: Nicolas L'Heureux, Todd N. McAllister, Nathalie Dusserre
-
Publication number: 20140271454Abstract: The present technology provides for a cell-synthesized biological particle, the processes for making a cell-synthesized particle, and a process for assembling such cell-synthesized particles into tissues and organs. The particles are synthesized in culture in vitro by living cells that produce natural extracellular matrix. Multiple particles can be assembled into tissues that have significant void space. The particles or tissues can act as a substrate for additional cell types. The particles or tissues can be further cultured in vitro to achieve favorable cell or extracellular matrix growth, organization or other desired characteristics. The particles or tissues can be devitalized or decellularized. The particles or tissues can be injected or implanted in a human to repair, enhance, or create a secretory, mechanical, or aesthetic function.Type: ApplicationFiled: April 23, 2012Publication date: September 18, 2014Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Nicolas L'Heureux, Todd N McAllister
-
Publication number: 20140081385Abstract: The technology described herein generally relates to the field of tissue engineering and treatment of cardiovascular disease by endovascular repair. The technology more particularly relates to devices and methods to produce a tissue-based implant that can be used for abdominal aorta aneurysm, thoracic aorta aneurysm, or other cardiovascular repair.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicant: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Sergio A. Garrido, Nicolas L'Heureux
-
Publication number: 20120150092Abstract: The invention includes methods and apparatus to deploy a blood vessel conduit via a catheter-based, percutaneous approach. In particular, a prosthetic blood conduit can be introduced around or through an arterial obstruction without requiring open bypass surgery. The technology includes coupling devices for docking the tips of two catheters, one situated inside a blood vessel, the other situated outside the blood vessel wall.Type: ApplicationFiled: March 17, 2010Publication date: June 14, 2012Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Todd N McAllister, Sergio A Garrido, Nicolas L'Heureux
-
Patent number: 8076137Abstract: The disclosure provides methods and compositions to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic.Type: GrantFiled: March 17, 2009Date of Patent: December 13, 2011Assignee: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Publication number: 20100189712Abstract: The present technology provides for a cell-synthesized biological thread, processes for making a cell-synthesized thread, and an apparatus for carrying out a process used to engineer the cell-synthesized thread. The thread is produced from living cells in culture and can be grown around the outer surface of a cylindrical bioreactor. The tissue comprising the thread has mechanical and biological properties achieved by altering the climactic conditions, stresses and strains on the tissue and chemical composition that prove beneficial in the medical industry. This process results in a biological thread that has high mechanical strength, decreased immunogenic effect and decreased thrombogenic effect when combined with other tissue. It also results in a product which can be used to create more complex constructs that otherwise could not have been generated. The threads can be used to make sutures, patches, and tubes, for example.Type: ApplicationFiled: November 19, 2007Publication date: July 29, 2010Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Nicolas L'Heureux, Todd N. McAllister
-
Patent number: 7744526Abstract: The invention relates to bioreactors having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling for the manufacture of a tissue engineered blood vessel (TEBV). The TEBV is made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding.Type: GrantFiled: August 25, 2006Date of Patent: June 29, 2010Assignee: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Publication number: 20100040663Abstract: The technology described herein generally relates to the field of tissue engineering and treatment of cardiovascular disease by endovascular repair. The technology more particularly relates to devices and methods to produce a tissue-based implant that can be used for abdominal aorta aneurysm, thoracic aorta aneurysm, or other cardiovascular repair.Type: ApplicationFiled: June 16, 2009Publication date: February 18, 2010Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Todd N. McAllister, Sergio A. Garrido, Nicolas L'Heureux
-
Publication number: 20090233356Abstract: The disclosure provides methods and compositions to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic.Type: ApplicationFiled: March 17, 2009Publication date: September 17, 2009Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Patent number: 7504258Abstract: The disclosure provides methods and composition to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic. The use of tissue manipulation devices further allows for the assembly of complex tissue engineered organs.Type: GrantFiled: December 11, 2002Date of Patent: March 17, 2009Assignee: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Publication number: 20070178588Abstract: The disclosure provides methods and systems for tissue engineering including an apparatus and methods for the growth, maintenance, and use of robust tissue sheets using tissue manipulation devices. The tissue manipulation devices provide a method of anchoring the tissue sheets to the cell culture substrate to promote prolonged maturation and subsequent increased mechanical strength. The tissue manipulation devices also provide a technique to facilitate removal of the sheet from the culture container and subsequent production steps to assemble more complex three dimensional organs from the robust sheet. The tissue manipulation devices also facilitate automated handling of the sheets in the assembly processes. The disclosure provides methods and composition derived from robust human sheets to build tissue engineered blood vessels, heart valves, stents, and endarterectomy patches and the like.Type: ApplicationFiled: December 14, 2006Publication date: August 2, 2007Applicant: Cytograft Tissue Engineering, Inc.Inventors: Todd McAllister, Nicolas L'Heureux
-
Patent number: 7166464Abstract: The disclosure provides methods and systems for tissue engineering including an apparatus and methods for the growth, maintenance, and use of robust tissue sheets using tissue manipulation devices. The tissue manipulation devices provide a method of anchoring the tissue sheets to the cell culture substrate to promote prolonged maturation and subsequent increased mechanical strength. The tissue manipulation devices also provide a technique to facilitate removal of the sheet from the culture container and subsequent production steps to assemble more complex three dimensional organs from the robust sheet. The tissue manipulation devices also facilitate automated handling of the sheets in the assembly processes. The disclosure provides methods and composition derived from robust human sheets to build tissue engineered blood vessels, heart valves, stents, and endarterectomy patches and the like.Type: GrantFiled: December 11, 2002Date of Patent: January 23, 2007Assignee: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Publication number: 20060286664Abstract: The invention relates to bioreactors having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling for the manufacture of a tissue engineered blood vessel (TEBV). The TEBV is made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding.Type: ApplicationFiled: August 25, 2006Publication date: December 21, 2006Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.Inventors: Todd McAllister, Nicolas L`Heureux
-
Patent number: 7112218Abstract: The invention is a tissue engineered blood vessel (TEBV) made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding. The TEBV is made in a bioreactor having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling.Type: GrantFiled: August 1, 2002Date of Patent: September 26, 2006Assignee: Cytograft Tissue Engineering, Inc.Inventors: Todd N. McAllister, Nicolas L'Heureux
-
Publication number: 20020188349Abstract: The invention is a tissue engineered blood vessel (TEBV) made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding. The TEBV is made in a bioreactor having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling.Type: ApplicationFiled: August 1, 2002Publication date: December 12, 2002Applicant: Cytograft Tissue Engineering, Inc., a California CorporationInventors: Todd N. McAllister, Nicolas L'Heureux